CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Drug Reimbursement Recommendation - Nerlynx, Tecentriq and Lynparza

December 5, 2019
Today, CADTH has issued final recommendations for: Nerlynx for Hormone Receptor-Positive Breast Cancer Funding Request: For patients with HER2-positive, hormone receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months. Recommendation: Do not reimburse Notification to implemen...

Drug Reimbursement Recommendation - lanadelumab (Takhzyro) + certolizumab pegol (Cimzia)

November 22, 2019
Today, CADTH has issued final recommendations for: lanadelumab (Takhzyro) Indications: Hereditary angioedema, prevention Recommendation: Reimburse with clinical criteria and/or conditions For more information certolizumab pegol (Cimzia) Indications: Psoriasis, moderate to severe plaque Recommendation: Reimburse with clinical criteria and/...

Drug Reimbursement Recommendation - teduglutide

November 21, 2019
Today, CADTH has issued final recommendations for: teduglutide (Revestive) Indications: Short Bowel Syndrome (SBS), pediatrics Recommendation: Reimburse with clinical criteria and/or conditions For more information

Drug Reimbursement Recommendation - cyclosporine (Verkazia)

November 20, 2019
Today, CADTH has issued recommendations for: cyclosporine (Verkazia) Indications : Severe vernal keratoconjunctivitis, pediatric (≥4 years) Recommendation : Reimburse with clinical criteria and/or conditions For more information

New at CADTH - November 2019

November 7, 2019
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.